ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer and Janssen form molecule-sharing pact

by Ryan Cross
October 27, 2018 | APPEARED IN VOLUME 96, ISSUE 43

The drug giants Pfizer and Janssen have formed a partnership in which they will share some of their unique molecules with each other for drug design. The collaboration is part of the Building Block Exchange (BBXC), which the duo has launched to facilitate one-for-one compound swaps. They hope more companies will join BBXC. Similarly, last year, Boehringer Ingelheim announced it would share molecules through its opnMe.com platform. In 2015, AstraZeneca and Sanofi agreed to exchange 210,000 compounds from their libraries.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment